In South Austin, father Jake Schneider says a brain implant from Neuralink has “given him wings” after amyotrophic lateral sclerosis steadily chipped away at his ability to move. Diagnosed in 2022, Schneider says the device lets him move a computer cursor, type through imagined movements, and even play video games after years of losing motor control. He still travels for regular checkups and says the implant has reshaped the time he spends with his six-year-old son.
Speaking with KXAN Austin, Schneider described the moment the device first switched on as feeling like he “got wings.” Within minutes, he was steering a cursor on-screen using only his thoughts. The outlet identified him as Neuralink’s seventh trial participant and walked through the mental-imagery typing tool he is using. Schneider also demonstrated how a removable charging cap powers the implant for several hours at a time.
How the implant works for him
Schneider and his online posts explain that the implant is a coin-sized device placed beneath the scalp and threaded into the motor cortex. Machine-learning software interprets his intention to move, then turns that signal into cursor motion or text. He maps different imagined movements to letters, the space bar and the enter key, a setup that let him type just minutes after the system was activated. Using the same mapping, he says he can control a Nintendo Switch gamepad to play titles like Mario Kart. For demonstrations and regular updates, he points people to Schneider's website, where he shares videos and how-tos.
Experts urge caution
Researchers and ethicists say early wins for brain-computer interfaces are real, but they come with big open questions about safety, durability and transparency. A June article in The Princeton Medical Review flagged concerns about limited public data sharing and unknown long-term effects. Reporting in The Guardian has also documented earlier technical hiccups with Neuralink devices that drew scrutiny from independent neuroscientists. Those voices emphasize that while implants can restore key functions in the short term, the field still lacks years-long safety data.
Where this fits in the clinical picture
Neuralink’s PRIME early-feasibility study began in 2024 and has expanded to multiple sites as the company looks for more participants and funding, according to industry reporting. MedTech Dive has covered the company’s fundraising and its plans to broaden patient access, and KXAN Austin noted that people with ALS were allowed into the protocol starting this summer. A review by the National Academies estimates that roughly 30,000 people in the United States are living with ALS and about 5,000 new cases are diagnosed each year, with average survival measured in three to five years after symptoms begin. That timeline helps explain why patients and families are watching BCI trials so closely.
Local context
Austin’s growing brain-computer interface ecosystem, from startups to clinical research groups, means stories like Schneider’s land close to home as well as on national radar. In March, nearby companies pushing similar technologies were highlighted for their parallel work in the field. Schneider, who posts updates online, says he travels to the Barrow Neurological Institute in Phoenix every three months for follow-up visits and has been sharing demos and advice with other trial participants through his website.
Schneider’s case underscores the balancing act at the heart of brain-computer interface research: immediate, life-changing gains for individual patients versus the longer, slower work of proving safety, durability and broad access. Clinicians and ethicists say it will take sustained follow-up and transparent data to show whether early breakthroughs like his can turn into reliable options for more people living with paralysis and ALS.
